Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Phase 4

Terminated

Conditions: Anemia

Interventions: Drug: sodium ferric gluconate
Drug: Oral Iron

First Posted Date: 2005-09-22

Last Posted Date: 2021-06-24

Lead Sponsor: Sanofi

Target Recruit Count: 112

Registration Number: NCT00223938

Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2005-09-15

Last Posted Date: 2009-04-08

Lead Sponsor: Sanofi

Target Recruit Count: 1145

Registration Number: NCT00174746

Locations: 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

CHOOSE : Telithromycin, Acute Bacterial Sinusitis

Phase 4

Completed

Conditions: Sinusitis

First Posted Date: 2005-09-15

Last Posted Date: 2009-09-25

Lead Sponsor: Sanofi

Target Recruit Count: 298

Registration Number: NCT00174694

Insulin Glulisine in Diabetes Mellitus, Type 2

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Therapy
Drug: Insulin Glulisine
Drug: Insulin Glargine

First Posted Date: 2005-09-15

Last Posted Date: 2009-09-15

Lead Sponsor: Sanofi

Target Recruit Count: 311

Registration Number: NCT00174668

Locations: 🇷🇴
Sanofi-aventis, Bucharest, Romania
🇬🇧
Sanofi-Aventis, Guildford, United Kingdom

Opposing Step-by-step Insulin Reinforcement to Intensified Strategy

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine
Drug: Insulin Glulisine
Drug: Metformin
Drug: insulin secretagogue

First Posted Date: 2005-09-15

Last Posted Date: 2009-09-15

Lead Sponsor: Sanofi

Target Recruit Count: 811

Registration Number: NCT00174642

Locations: 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2005-09-15

Last Posted Date: 2009-04-08

Lead Sponsor: Sanofi

Target Recruit Count: 708

Registration Number: NCT00174720

Locations: 🇷🇺
Sanofi-Aventis Administrative Office, Moscow, Russian Federation

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

Phase 3

Completed

Conditions: Asthma

First Posted Date: 2005-09-15

Last Posted Date: 2009-04-08

Lead Sponsor: Sanofi

Target Recruit Count: 456

Registration Number: NCT00174733

Locations: 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States

Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections

Phase 3

Terminated

Conditions: Otitis Media

First Posted Date: 2005-09-15

Last Posted Date: 2009-04-03

Lead Sponsor: Sanofi

Target Recruit Count: 639

Registration Number: NCT00174811

Locations: 🇫🇷
Sanofi- Aventis Administrative Office, Paris, France
🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States